JP6566450B2 - 発泡組成物及びそれを製造する方法 - Google Patents
発泡組成物及びそれを製造する方法 Download PDFInfo
- Publication number
- JP6566450B2 JP6566450B2 JP2017535153A JP2017535153A JP6566450B2 JP 6566450 B2 JP6566450 B2 JP 6566450B2 JP 2017535153 A JP2017535153 A JP 2017535153A JP 2017535153 A JP2017535153 A JP 2017535153A JP 6566450 B2 JP6566450 B2 JP 6566450B2
- Authority
- JP
- Japan
- Prior art keywords
- acid
- composition
- granulation
- granules
- input blend
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 235
- 239000006260 foam Substances 0.000 title claims description 66
- 238000004519 manufacturing process Methods 0.000 title description 11
- 239000002253 acid Substances 0.000 claims description 137
- 238000000034 method Methods 0.000 claims description 75
- 238000005469 granulation Methods 0.000 claims description 72
- 230000003179 granulation Effects 0.000 claims description 72
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 54
- 238000002844 melting Methods 0.000 claims description 47
- 230000008018 melting Effects 0.000 claims description 46
- 239000003979 granulating agent Substances 0.000 claims description 32
- 238000011065 in-situ storage Methods 0.000 claims description 28
- 239000001569 carbon dioxide Substances 0.000 claims description 27
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 27
- -1 anti-inflammatory Substances 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 7
- 150000008065 acid anhydrides Chemical class 0.000 claims description 6
- 230000000202 analgesic effect Effects 0.000 claims description 4
- 230000001088 anti-asthma Effects 0.000 claims description 4
- 230000000844 anti-bacterial effect Effects 0.000 claims description 4
- 230000001773 anti-convulsant effect Effects 0.000 claims description 4
- 230000001430 anti-depressive effect Effects 0.000 claims description 4
- 230000003178 anti-diabetic effect Effects 0.000 claims description 4
- 230000003276 anti-hypertensive effect Effects 0.000 claims description 4
- 230000002924 anti-infective effect Effects 0.000 claims description 4
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 4
- 230000000118 anti-neoplastic effect Effects 0.000 claims description 4
- 230000002141 anti-parasite Effects 0.000 claims description 4
- 230000000561 anti-psychotic effect Effects 0.000 claims description 4
- 230000000840 anti-viral effect Effects 0.000 claims description 4
- 239000000924 antiasthmatic agent Substances 0.000 claims description 4
- 239000003146 anticoagulant agent Substances 0.000 claims description 4
- 229940127219 anticoagulant drug Drugs 0.000 claims description 4
- 239000001961 anticonvulsive agent Substances 0.000 claims description 4
- 239000000935 antidepressant agent Substances 0.000 claims description 4
- 229940005513 antidepressants Drugs 0.000 claims description 4
- 239000003472 antidiabetic agent Substances 0.000 claims description 4
- 229960003965 antiepileptics Drugs 0.000 claims description 4
- 229940121375 antifungal agent Drugs 0.000 claims description 4
- 239000000739 antihistaminic agent Substances 0.000 claims description 4
- 239000003096 antiparasitic agent Substances 0.000 claims description 4
- 239000000850 decongestant Substances 0.000 claims description 4
- 239000002934 diuretic Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000003792 electrolyte Substances 0.000 claims description 4
- 239000003172 expectorant agent Substances 0.000 claims description 4
- 230000003419 expectorant effect Effects 0.000 claims description 4
- 239000008141 laxative Substances 0.000 claims description 4
- 239000003158 myorelaxant agent Substances 0.000 claims description 4
- 241000224489 Amoeba Species 0.000 claims description 3
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims description 3
- 241000224526 Trichomonas Species 0.000 claims description 3
- 239000013543 active substance Substances 0.000 claims description 3
- 230000002456 anti-arthritic effect Effects 0.000 claims description 3
- 230000000843 anti-fungal effect Effects 0.000 claims description 3
- 230000001387 anti-histamine Effects 0.000 claims description 3
- 125000005587 carbonate group Chemical group 0.000 claims description 3
- 230000001882 diuretic effect Effects 0.000 claims description 3
- 230000002475 laxative effect Effects 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 229940034982 antineoplastic agent Drugs 0.000 claims description 2
- 150000008064 anhydrides Chemical class 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 1
- 239000008187 granular material Substances 0.000 description 107
- 239000002585 base Substances 0.000 description 51
- 238000012545 processing Methods 0.000 description 45
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 28
- 239000007938 effervescent tablet Substances 0.000 description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
- 239000003826 tablet Substances 0.000 description 22
- 239000008184 oral solid dosage form Substances 0.000 description 17
- 238000005187 foaming Methods 0.000 description 15
- 230000008569 process Effects 0.000 description 15
- 230000000717 retained effect Effects 0.000 description 15
- 239000008186 active pharmaceutical agent Substances 0.000 description 13
- 239000011230 binding agent Substances 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 13
- 239000000463 material Substances 0.000 description 11
- 239000000654 additive Substances 0.000 description 10
- 239000000796 flavoring agent Substances 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 10
- 230000000977 initiatory effect Effects 0.000 description 10
- 238000007796 conventional method Methods 0.000 description 9
- 238000005550 wet granulation Methods 0.000 description 9
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 8
- 150000007513 acids Chemical class 0.000 description 8
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 8
- 229960004106 citric acid Drugs 0.000 description 8
- 235000015165 citric acid Nutrition 0.000 description 8
- 239000003086 colorant Substances 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 230000007704 transition Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 239000000314 lubricant Substances 0.000 description 7
- 239000000155 melt Substances 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 238000001035 drying Methods 0.000 description 6
- 235000013355 food flavoring agent Nutrition 0.000 description 6
- 230000014759 maintenance of location Effects 0.000 description 6
- 235000013305 food Nutrition 0.000 description 5
- 238000004806 packaging method and process Methods 0.000 description 5
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 4
- 239000001361 adipic acid Substances 0.000 description 4
- 235000011037 adipic acid Nutrition 0.000 description 4
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 238000010411 cooking Methods 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 235000015872 dietary supplement Nutrition 0.000 description 4
- 238000007599 discharging Methods 0.000 description 4
- 239000007884 disintegrant Substances 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 230000002363 herbicidal effect Effects 0.000 description 4
- 238000003898 horticulture Methods 0.000 description 4
- 230000000749 insecticidal effect Effects 0.000 description 4
- 238000004898 kneading Methods 0.000 description 4
- 239000001630 malic acid Substances 0.000 description 4
- 235000011090 malic acid Nutrition 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000011975 tartaric acid Substances 0.000 description 4
- 235000002906 tartaric acid Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000011437 continuous method Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 241000167854 Bourreria succulenta Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 235000016623 Fragaria vesca Nutrition 0.000 description 2
- 240000009088 Fragaria x ananassa Species 0.000 description 2
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 235000009754 Vitis X bourquina Nutrition 0.000 description 2
- 235000012333 Vitis X labruscana Nutrition 0.000 description 2
- 240000006365 Vitis vinifera Species 0.000 description 2
- 235000014787 Vitis vinifera Nutrition 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229960004543 anhydrous citric acid Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 238000010923 batch production Methods 0.000 description 2
- 229960002129 cefixime Drugs 0.000 description 2
- OKBVVJOGVLARMR-QSWIMTSFSA-N cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 description 2
- 235000019693 cherries Nutrition 0.000 description 2
- 238000007907 direct compression Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000007908 dry granulation Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000012943 hotmelt Substances 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000010128 melt processing Methods 0.000 description 2
- 239000006191 orally-disintegrating tablet Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 150000003839 salts Chemical group 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229940083542 sodium Drugs 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 235000019499 Citrus oil Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 244000004281 Eucalyptus maculata Species 0.000 description 1
- RZSYLLSAWYUBPE-UHFFFAOYSA-L Fast green FCF Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC(O)=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 RZSYLLSAWYUBPE-UHFFFAOYSA-L 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 240000001987 Pyrus communis Species 0.000 description 1
- 240000007651 Rubus glaucus Species 0.000 description 1
- 235000011034 Rubus glaucus Nutrition 0.000 description 1
- 235000009122 Rubus idaeus Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 240000006909 Tilia x europaea Species 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 244000263375 Vanilla tahitensis Species 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 230000003569 amebicidal effect Effects 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 239000010617 anise oil Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000005844 autocatalytic reaction Methods 0.000 description 1
- 239000010620 bay oil Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 235000012745 brilliant blue FCF Nutrition 0.000 description 1
- 239000004161 brilliant blue FCF Substances 0.000 description 1
- 239000008372 bubblegum flavor Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- OCHFNTLZOZPXFE-JEDNCBNOSA-N carbonic acid;(2s)-2,6-diaminohexanoic acid Chemical compound OC(O)=O.NCCCC[C@H](N)C(O)=O OCHFNTLZOZPXFE-JEDNCBNOSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229940119201 cedar leaf oil Drugs 0.000 description 1
- OIQPTROHQCGFEF-UHFFFAOYSA-L chembl1371409 Chemical compound [Na+].[Na+].OC1=CC=C2C=C(S([O-])(=O)=O)C=CC2=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 OIQPTROHQCGFEF-UHFFFAOYSA-L 0.000 description 1
- CEZCCHQBSQPRMU-UHFFFAOYSA-L chembl174821 Chemical compound [Na+].[Na+].COC1=CC(S([O-])(=O)=O)=C(C)C=C1N=NC1=C(O)C=CC2=CC(S([O-])(=O)=O)=CC=C12 CEZCCHQBSQPRMU-UHFFFAOYSA-L 0.000 description 1
- 239000007958 cherry flavor Substances 0.000 description 1
- 239000010630 cinnamon oil Substances 0.000 description 1
- 239000010500 citrus oil Substances 0.000 description 1
- 239000010634 clove oil Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- RRPFCKLVOUENJB-UHFFFAOYSA-L disodium;2-aminoacetic acid;carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O.NCC(O)=O RRPFCKLVOUENJB-UHFFFAOYSA-L 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000007911 effervescent powder Substances 0.000 description 1
- 229940037395 electrolytes Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- IINNWAYUJNWZRM-UHFFFAOYSA-L erythrosin B Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 IINNWAYUJNWZRM-UHFFFAOYSA-L 0.000 description 1
- 235000012732 erythrosine Nutrition 0.000 description 1
- 239000004174 erythrosine Substances 0.000 description 1
- 229940011411 erythrosine Drugs 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 229940066493 expectorants Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000019240 fast green FCF Nutrition 0.000 description 1
- 229940051147 fd&c yellow no. 6 Drugs 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 1
- 229940046813 glyceryl palmitostearate Drugs 0.000 description 1
- 238000009474 hot melt extrusion Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 229960005236 ibandronic acid Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- KHLVKKOJDHCJMG-QDBORUFSSA-L indigo carmine Chemical compound [Na+].[Na+].N/1C2=CC=C(S([O-])(=O)=O)C=C2C(=O)C\1=C1/NC2=CC=C(S(=O)(=O)[O-])C=C2C1=O KHLVKKOJDHCJMG-QDBORUFSSA-L 0.000 description 1
- 235000012738 indigotine Nutrition 0.000 description 1
- 239000004179 indigotine Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940125722 laxative agent Drugs 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 229940037627 magnesium lauryl sulfate Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000001627 myristica fragrans houtt. fruit oil Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000590 phytopharmaceutical Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 239000001327 prunus amygdalus amara l. extract Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000009490 roller compaction Methods 0.000 description 1
- 239000010670 sage oil Substances 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 229940071207 sesquicarbonate Drugs 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 238000009491 slugging Methods 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000001757 thermogravimetry curve Methods 0.000 description 1
- 239000001789 thuja occidentalis l. leaf oil Substances 0.000 description 1
- 239000010678 thyme oil Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- UJMBCXLDXJUMFB-UHFFFAOYSA-K trisodium;5-oxo-1-(4-sulfonatophenyl)-4-[(4-sulfonatophenyl)diazenyl]-4h-pyrazole-3-carboxylate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-UHFFFAOYSA-K 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
- A23P10/25—Agglomeration or granulation by extrusion or by pressing, e.g. through small holes, through sieves or between surfaces
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29B—PREPARATION OR PRETREATMENT OF THE MATERIAL TO BE SHAPED; MAKING GRANULES OR PREFORMS; RECOVERY OF PLASTICS OR OTHER CONSTITUENTS OF WASTE MATERIAL CONTAINING PLASTICS
- B29B7/00—Mixing; Kneading
- B29B7/002—Methods
- B29B7/007—Methods for continuous mixing
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29B—PREPARATION OR PRETREATMENT OF THE MATERIAL TO BE SHAPED; MAKING GRANULES OR PREFORMS; RECOVERY OF PLASTICS OR OTHER CONSTITUENTS OF WASTE MATERIAL CONTAINING PLASTICS
- B29B7/00—Mixing; Kneading
- B29B7/30—Mixing; Kneading continuous, with mechanical mixing or kneading devices
- B29B7/34—Mixing; Kneading continuous, with mechanical mixing or kneading devices with movable mixing or kneading devices
- B29B7/38—Mixing; Kneading continuous, with mechanical mixing or kneading devices with movable mixing or kneading devices rotary
- B29B7/46—Mixing; Kneading continuous, with mechanical mixing or kneading devices with movable mixing or kneading devices rotary with more than one shaft
- B29B7/48—Mixing; Kneading continuous, with mechanical mixing or kneading devices with movable mixing or kneading devices rotary with more than one shaft with intermeshing devices, e.g. screws
- B29B7/482—Mixing; Kneading continuous, with mechanical mixing or kneading devices with movable mixing or kneading devices rotary with more than one shaft with intermeshing devices, e.g. screws provided with screw parts in addition to other mixing parts, e.g. paddles, gears, discs
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29B—PREPARATION OR PRETREATMENT OF THE MATERIAL TO BE SHAPED; MAKING GRANULES OR PREFORMS; RECOVERY OF PLASTICS OR OTHER CONSTITUENTS OF WASTE MATERIAL CONTAINING PLASTICS
- B29B7/00—Mixing; Kneading
- B29B7/30—Mixing; Kneading continuous, with mechanical mixing or kneading devices
- B29B7/34—Mixing; Kneading continuous, with mechanical mixing or kneading devices with movable mixing or kneading devices
- B29B7/38—Mixing; Kneading continuous, with mechanical mixing or kneading devices with movable mixing or kneading devices rotary
- B29B7/46—Mixing; Kneading continuous, with mechanical mixing or kneading devices with movable mixing or kneading devices rotary with more than one shaft
- B29B7/48—Mixing; Kneading continuous, with mechanical mixing or kneading devices with movable mixing or kneading devices rotary with more than one shaft with intermeshing devices, e.g. screws
- B29B7/488—Parts, e.g. casings, sealings; Accessories, e.g. flow controlling or throttling devices
- B29B7/489—Screws
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29B—PREPARATION OR PRETREATMENT OF THE MATERIAL TO BE SHAPED; MAKING GRANULES OR PREFORMS; RECOVERY OF PLASTICS OR OTHER CONSTITUENTS OF WASTE MATERIAL CONTAINING PLASTICS
- B29B9/00—Making granules
- B29B9/02—Making granules by dividing preformed material
- B29B9/06—Making granules by dividing preformed material in the form of filamentary material, e.g. combined with extrusion
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29B—PREPARATION OR PRETREATMENT OF THE MATERIAL TO BE SHAPED; MAKING GRANULES OR PREFORMS; RECOVERY OF PLASTICS OR OTHER CONSTITUENTS OF WASTE MATERIAL CONTAINING PLASTICS
- B29B9/00—Making granules
- B29B9/12—Making granules characterised by structure or composition
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
- B29C48/022—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor characterised by the choice of material
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
- B29C48/03—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor characterised by the shape of the extruded material at extrusion
- B29C48/04—Particle-shaped
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
- B29C48/25—Component parts, details or accessories; Auxiliary operations
- B29C48/36—Means for plasticising or homogenising the moulding material or forcing it through the nozzle or die
- B29C48/395—Means for plasticising or homogenising the moulding material or forcing it through the nozzle or die using screws surrounded by a cooperating barrel, e.g. single screw extruders
- B29C48/40—Means for plasticising or homogenising the moulding material or forcing it through the nozzle or die using screws surrounded by a cooperating barrel, e.g. single screw extruders using two or more parallel screws or at least two parallel non-intermeshing screws, e.g. twin screw extruders
- B29C48/405—Intermeshing co-rotating screws
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
- B29C48/25—Component parts, details or accessories; Auxiliary operations
- B29C48/36—Means for plasticising or homogenising the moulding material or forcing it through the nozzle or die
- B29C48/50—Details of extruders
- B29C48/505—Screws
- B29C48/535—Screws with thread pitch varying along the longitudinal axis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
- B29C48/25—Component parts, details or accessories; Auxiliary operations
- B29C48/36—Means for plasticising or homogenising the moulding material or forcing it through the nozzle or die
- B29C48/50—Details of extruders
- B29C48/505—Screws
- B29C48/54—Screws with additional forward-feeding elements
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
- B29C48/25—Component parts, details or accessories; Auxiliary operations
- B29C48/92—Measuring, controlling or regulating
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C2948/00—Indexing scheme relating to extrusion moulding
- B29C2948/92—Measuring, controlling or regulating
- B29C2948/92504—Controlled parameter
- B29C2948/92704—Temperature
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mechanical Engineering (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Glanulating (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- General Preparation And Processing Of Foods (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Detergent Compositions (AREA)
Description
以下の用語説明は、本開示をよりよく説明し、本開示の実施において当業者を導くために提供される。本明細書で使用する場合、「含む(comprising)」は、「含むがこれらに限定されない(including but not limited to)」ことを意味し、単数形「1つ(種)の(a)」若しくは「1つ(種)の(an」又は「その(the)」は、文脈上明らかに別段の指定がない限り、複数の指示対象を含む。「又は」という用語は、文脈上明らかに別段の指示がない限り、記述された択一的要素のうちの単一の要素又は2つ以上の要素の組合せを指す。
本開示は、多孔性発泡組成物、より詳細には顆粒に関する。組成物は、1つ又は複数の重要な属性、例えば自由流動能力、圧縮性、多孔度、相当量の二酸化炭素保持及び機械的強度を有する。顆粒の形態の発泡組成物は、それ自体を使用することができ、使用する前に他の添加剤と混合することができ、又は例えば、所望の機械的強度、有効性及び急速な崩壊時間を有する発泡錠を形成するのに好適である。一部の実施形態では、本開示の顆粒の形態の多孔性発泡組成物は、投入ブレンドの多孔度よりも少なくとも50%大きい多孔度を有し、投入ブレンドの二酸化炭素(CO2)含有量の全て又は実質的に全てを保持する。本明細書において、投入ブレンドに対する発泡組成物の多孔度は、相対多孔度と称される。相対多孔度は、相対かさ多孔度又は相対タップ多孔度のいずれかとして測定されうる。「投入ブレンドのCO2含有量の全て又は実質的に全て」という用語は、投入ブレンドのCO2含有量の少なくとも90%を意味し、組成物、詳細には顆粒のパーセント相対保持CO2含有率としても表される。
多様な用途における組成物の使用に寄与する改善された特性を示す多孔性発泡組成物の実施形態が、本明細書に開示される。一部の実施形態では、多孔性発泡組成物は、酸及び塩基を含む投入ブレンドを使用して形成することができる。一部の実施形態では、多孔性発泡組成物は、投入ブレンドの多孔度よりも少なくとも50%大きい多孔度を有する。一部の実施形態では、多孔性発泡組成物は、投入ブレンドの少なくとも90%の保持二酸化炭素含有率を有する。顆粒の多孔度の増加を、顆粒の他の特性を損なうことなく達成できることが観察された。
SEI=SEI機械的+SEI熱的
酸溶融パーセント=SEI/Em×100……(1)
(式中、酸の完全溶融に必要とされるエネルギー(Em)は、投入ブレンド及びその成分の示差走査熱量測定(DSC)サーモグラムから得ることができる)。
P=2πNτ/60,000……(2)
(式中、P=出力(kW)
N=スクリュー速度(rpm)
τ=トルク(Nm))
SEI機械的=出力(kW)/スループット又は供給速度(kg/h)……(3)
(式中、SEI機械的は、二軸スクリュー加工機の機械的比エネルギー投入量(kWh/kg)である)。
本明細書に開示された組成物、方法及び加工機の実施形態は、重要な属性、例えば従来の類似の発泡組成物と比較してより高い多孔度及びより高い二酸化炭素含有量を有する発泡組成物の生産を実現する。これらの多孔性発泡組成物は、加工添加剤を使用して更に加工して、例えば、改善された機械的強度を示し、且つ一般に60秒未満の急速な崩壊時間も示す発泡錠を形成することができる。
特許請求された方法の実施形態を使用して形成された多孔性発泡組成物、詳細には顆粒の水分含有率、保持CO2含有率、崩壊時間、多孔度、かさ密度及びタップ密度、並びに他の特性を決定するための例が、本明細書に記載される。いくつかの例は、従来方法と比較して、本開示の組成物及び方法を使用することの利益を強調する。
相対保持CO2含有率(%)=(顆粒中のCO2の観測質量(g)×100)/投入ブレンド中のCO2の観測質量(g)
かさ密度=質量(m)/かさ体積(V0)
タップ密度=質量(m)/タップ体積(Vt)
相対かさ多孔度%=((顆粒1gのかさ比体積-投入ブレンド1gのかさ比体積)×100)/投入ブレンド1gのかさ比体積
(式中、顆粒1gのかさ比体積=1/顆粒のかさ密度、及び
投入ブレンド1gのかさ比体積=1/投入ブレンドのかさ密度)
相対タップ多孔度%=((顆粒1gのタップ比体積-投入ブレンド1gのタップ比体積)×100)/投入ブレンド1gのタップ比体積
(式中、顆粒1gのタップ比体積=1/顆粒のタップ密度
投入ブレンド1gのタップ比体積=1/投入ブレンドのタップ密度)
本開示による多孔性発泡組成物の調製:
4つの実験を実施して、異なる酸を含む例示的な顆粒を形成した。例示的な顆粒を形成するために使用した成分を下記に挙げる。
相対保持CO2含有率%=(顆粒中のCO2の観測質量(g)×100)/投入ブレンド中のCO2の観測質量(g)
相対保持CO2含有率%=(1.36×100)/1.43=95.10
顆粒1gのかさ比体積=1/顆粒のかさ密度
投入ブレンド1gのかさ比体積=1/投入ブレンドのかさ密度
相対かさ多孔度%=((顆粒1gのかさ比体積-投入ブレンド1gのかさ比体積)×100)/投入ブレンド1gのかさ比体積
顆粒1gのかさ比体積=1/0.389=2.570
投入ブレンド1gのかさ比体積=1/0.680=1.470
相対かさ多孔度%=(2.57-1.47×100)/1.47=74.81
顆粒1gのタップ比体積=1/顆粒のタップ密度
投入ブレンド1gのタップ比体積=1/投入ブレンドのタップ密度
相対タップ多孔度%=((顆粒1gのタップ比体積-投入ブレンド1gのタップ比体積)×100)/投入ブレンド1gのタップ比体積
顆粒1gのタップ比体積=1/0.555=1.801
投入ブレンド1gのタップ比体積=1/1.137=0.879
相対タップ多孔度%=(1.801-0.879×100)/0.879=104.86
例示的な発泡錠の調製
実施例1に記載した4つの実験において得られた例示的な顆粒1〜4を、乾燥減量が0.5w/w%になるまで45℃に維持した。乾燥した顆粒を、ASTMメッシュ20番篩に通した。上記の工程からの顆粒を、20mm丸平面はす縁ツーリングを備えた単一ステーションの卓上Inweka打錠機(Ahmedabad、インド)を使用して、2.5グラムの質量の錠剤に圧縮した。次いで、錠剤を評価して、その特性を決定した。4つの実験において得られた錠剤の特性を、下記のTable 5(表6)に要約した。
APIを含む発泡錠の調製
3つの実験を実施して、API-アスピリン、N-アセチル-L-システイン(NAC)及びセフィキシムを含む発泡錠を形成した。発泡錠を形成するために使用した成分を下記に示す。
積極的に添加される造粒剤として溶融性結合剤を使用することによる発泡顆粒の調製
1つの例では、積極的に添加される結合剤を使用して顆粒を形成する方法を使用して、錠剤を製造した。この例における錠剤を形成するために使用した成分を下記に示す。
溶融している酸の一部及び溶融していない酸の一部の組合せを含む無水酸成分と、カーボネート官能基を含み、酸成分と反応して二酸化炭素を形成することが可能である無水塩基成分とを含む顆粒状組成物であって、無水酸成分及び無水塩基成分が、1:9から9:1の範囲の質量比で存在する、積極的に添加される造粒剤を含まない、組成物。
202 取入れゾーン
204 造粒開始ゾーン
206 造粒完了ゾーン
208 出口
Claims (4)
- 無水酸成分と、
カーボネート官能基を含み、酸成分と反応して二酸化炭素を形成することが可能である無水塩基成分と
を含む顆粒状発泡組成物であって、
無水酸成分及び無水塩基成分が1:9から9:1の範囲の質量比で存在し、
組成物が、in situ造粒剤によって形成され、
前記in situ造粒剤が、造粒中に溶融した前記無水酸成分の一部であり、
前記in situ造粒剤以外の造粒剤を含まない、組成物。 - 抗感染症薬、抗細菌薬、抗ヒスタミン薬、鬱血除去薬、抗炎症薬、抗寄生虫薬、抗ウイルス薬、抗真菌薬、殺アメーバ薬、殺トリコモナス剤、鎮痛薬、抗関節炎薬、抗喘息薬、抗凝固薬、抗けいれん薬、抗鬱薬、抗糖尿病薬、抗新生物薬、抗精神病薬、降圧薬、去痰薬、電解質、緩下薬、植物性医薬品、筋弛緩薬、利尿薬、又はそれらの組合せからなる群から選択される医薬活性作用物質を更に含む、請求項1に記載の組成物。
- 顆粒状発泡組成物を調製するための方法であって、
1:9から9:1の範囲の質量比の無水酸成分及び無水塩基成分を含む投入ブレンドを二軸スクリュー加工機に供給する工程と、
in situ造粒剤として機能するように、前記無水酸成分の一部のみを溶融させる工程と、
投入ブレンドを造粒して、前記in situ造粒剤以外の造粒剤を含まない顆粒状発泡組成物を形成する工程と、
任意選択で、二軸スクリュー加工機から顆粒状発泡組成物を回収する工程と
を含む、方法。 - 前記投入ブレンドが、抗感染症薬、抗細菌薬、抗ヒスタミン薬、鬱血除去薬、抗炎症薬、抗寄生虫薬、抗ウイルス薬、抗真菌薬、殺アメーバ薬、殺トリコモナス剤、鎮痛薬、抗関節炎薬、抗喘息薬、抗凝固薬、抗けいれん薬、抗鬱薬、抗糖尿病薬、抗新生物薬、抗精神病薬、降圧薬、去痰薬、電解質、緩下薬、植物性医薬品、筋弛緩薬、利尿薬、又はそれらの組合せからなる群から選択される医薬活性作用物質を更に含む、請求項3に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN4527/CHE/2014 | 2014-09-17 | ||
IN4527CH2014 | 2014-09-17 | ||
PCT/IB2015/000400 WO2016042372A1 (en) | 2014-09-17 | 2015-03-26 | Effervescent composition and method of making it |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018061956A Division JP6748138B2 (ja) | 2014-09-17 | 2018-03-28 | 発泡組成物及びそれを製造する方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017529399A JP2017529399A (ja) | 2017-10-05 |
JP6566450B2 true JP6566450B2 (ja) | 2019-08-28 |
Family
ID=53051839
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017535153A Active JP6566450B2 (ja) | 2014-09-17 | 2015-03-26 | 発泡組成物及びそれを製造する方法 |
JP2018061956A Active JP6748138B2 (ja) | 2014-09-17 | 2018-03-28 | 発泡組成物及びそれを製造する方法 |
JP2019124482A Active JP7010890B2 (ja) | 2014-09-17 | 2019-07-03 | 発泡組成物及びそれを製造する方法 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018061956A Active JP6748138B2 (ja) | 2014-09-17 | 2018-03-28 | 発泡組成物及びそれを製造する方法 |
JP2019124482A Active JP7010890B2 (ja) | 2014-09-17 | 2019-07-03 | 発泡組成物及びそれを製造する方法 |
Country Status (10)
Country | Link |
---|---|
US (2) | US20170252295A1 (ja) |
EP (1) | EP3193843A1 (ja) |
JP (3) | JP6566450B2 (ja) |
KR (1) | KR102193599B1 (ja) |
CN (1) | CN106714783A (ja) |
AU (2) | AU2015316552C1 (ja) |
BR (1) | BR112017005362A2 (ja) |
CA (2) | CA3018828C (ja) |
RU (1) | RU2706727C2 (ja) |
WO (1) | WO2016042372A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017098481A1 (en) | 2015-12-12 | 2017-06-15 | Steerlife India Private Limited | Effervescent compositions of metformin and processes for preparation thereof |
AR108302A1 (es) * | 2016-04-22 | 2018-08-08 | Univ Mississippi | Granulación en seco con doble husillo para producir formulaciones sólidas |
CA3116459A1 (en) * | 2018-11-26 | 2020-06-04 | Purac Biochem B.V. | Particulate food preservative composition |
JP7494421B2 (ja) | 2020-05-29 | 2024-06-04 | アース製薬株式会社 | 顆粒配合発泡打錠剤 |
GR1010127B (el) * | 2020-06-30 | 2021-11-16 | Βεννεττ Φαρμακευτικη A.E., | Αναβραζοντα κοκκια που περιεχουν αλατα μαγνησιου |
Family Cites Families (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1450865A (en) * | 1922-05-05 | 1923-04-03 | Pelc Joseph | Water-soluble product and process of making the same |
US2071841A (en) | 1935-06-14 | 1937-02-23 | Int Patents Dev Co | Coating process |
US2988562A (en) | 1953-04-29 | 1961-06-13 | Du Pont | Process for preparing a monoacyl dicyclopentadienyl iron |
US2851361A (en) | 1955-06-22 | 1958-09-09 | Henry Brout | Carbonated drink and concentrate for producing same |
US4004036A (en) | 1966-05-31 | 1977-01-18 | Alberto Culver Company | Effervescent molded triturate tablets |
GB1300969A (en) | 1969-03-26 | 1972-12-29 | Organon Nv | Novel modified acid crystals and a process for their preparation |
GB1338071A (en) | 1970-11-25 | 1973-11-21 | Laso Martinez V | Pharmaceutical iron preparations |
GB1359614A (en) | 1971-04-06 | 1974-07-10 | Dev Et De Rech Soc Fr De | Method for the manufacture of effervescent tablets |
GB1548022A (en) | 1976-10-06 | 1979-07-04 | Wyeth John & Brother Ltd | Pharmaceutial dosage forms |
CA1097233A (en) | 1977-07-20 | 1981-03-10 | George K. E. Gregory | Packages |
US4252664A (en) * | 1978-10-30 | 1981-02-24 | Colgate-Palmolive Company | Effervescent granules |
CA1209040A (fr) | 1982-12-21 | 1986-08-05 | Jean Bru | Procede de fabrication de granules et comprimes effervescents |
DE3332629A1 (de) * | 1983-09-09 | 1985-03-28 | Hermann Berstorff Maschinenbau Gmbh, 3000 Hannover | Verfahren und vorrichtung zum pulverisieren von polymeren |
US4678661A (en) | 1983-09-28 | 1987-07-07 | Gerhard Gergely | Effervescent composition and method of making same |
IE59106B1 (en) | 1985-05-31 | 1994-01-12 | Warner Lambert Co | A therapeutic effervescent composition and a method of preparing the same |
FR2593065B1 (fr) | 1986-01-22 | 1988-09-09 | Smith Kline French Lab | Couples effervescents, compositions effervescentes d'antagonistes h2 de l'histamine les contenant et leur preparation. |
US5019302A (en) | 1986-03-12 | 1991-05-28 | Washington University Technology Associates, Inc. | Method for granulation |
GB8724763D0 (en) | 1987-10-22 | 1987-11-25 | Aps Research Ltd | Sustained-release formulations |
US5178878A (en) | 1989-10-02 | 1993-01-12 | Cima Labs, Inc. | Effervescent dosage form with microparticles |
US5188825A (en) | 1989-12-28 | 1993-02-23 | Iles Martin C | Freeze-dried dosage forms and methods for preparing the same |
ATE108649T1 (de) | 1990-02-14 | 1994-08-15 | Takeda Chemical Industries Ltd | Brausemischung, deren herstellung sowie verwendung. |
AU639137B2 (en) | 1990-09-21 | 1993-07-15 | Merrell Dow Pharmaceuticals Inc. | Superior tasting pharmaceutical composition having porous particles and the process of preparing such pharmaceutical composition |
HUT75616A (en) | 1992-03-17 | 1997-05-28 | Pfizer | Method for prooucing porous delivery devices |
DE69429119T2 (de) | 1993-07-09 | 2002-07-18 | R.P. Scherer Corp., Troy | Verfahren zur herstellung von gefriergetrockneten arzneistoffdosierungsformen |
IL112779A (en) | 1994-03-01 | 1999-11-30 | Gergely Gerhard | Granular product or tablet containing an efferescent system and an active pharmaceutical substance and its preparation |
DE4418837A1 (de) | 1994-05-30 | 1995-12-07 | Bayer Ag | Thermisches Granulierverfahren |
US5738875A (en) | 1994-10-28 | 1998-04-14 | R.P. Scherer Corporation | Process for preparing solid pharmaceutical dosage forms |
GB9421836D0 (en) | 1994-10-28 | 1994-12-14 | Scherer Corp R P | Process for preparing solid pharmaceutical dosage forms of hydrophobic substances |
FR2726469B1 (fr) | 1994-11-08 | 1996-12-13 | Adir | Composition pharmaceutique pour l'administration orale de flavonoides |
US5750061A (en) | 1995-11-07 | 1998-05-12 | Lonza Inc. | Halohydantoin forms produced by melt extrusion and method for making |
GB2307857B (en) | 1995-12-04 | 1999-01-27 | Euro Celtique Sa | An effervescent formulation |
SE512835C2 (sv) | 1996-01-08 | 2000-05-22 | Astrazeneca Ab | Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare |
US5853759A (en) | 1996-05-17 | 1998-12-29 | Merck & Co.. Inc. | Effervescent alendronate formulation |
DE19624607A1 (de) | 1996-06-20 | 1998-01-02 | Basf Ag | Verfahren zur Herstellung von Salzen von Säuregruppen tragenden pharmazeutischen Wirkstoffen |
BR9710732B1 (pt) | 1996-07-18 | 2009-08-11 | extrusor de cozinhar de pequeno comprimento e método de cozinhar com extrusão um material comestìvel. | |
US6488961B1 (en) | 1996-09-20 | 2002-12-03 | Ethypharm, Inc. | Effervescent granules and methods for their preparation |
US6071539A (en) | 1996-09-20 | 2000-06-06 | Ethypharm, Sa | Effervescent granules and methods for their preparation |
US6649186B1 (en) | 1996-09-20 | 2003-11-18 | Ethypharm | Effervescent granules and methods for their preparation |
US20010006677A1 (en) | 1996-10-29 | 2001-07-05 | Mcginity James W. | Effervescence polymeric film drug delivery system |
EP0872544A1 (en) * | 1997-04-14 | 1998-10-21 | The Procter & Gamble Company | Dry effervescent granules and granular compositions comprising the same |
CN1260827A (zh) | 1997-04-14 | 2000-07-19 | 普罗格特-甘布尔公司 | 发泡组分 |
US6024981A (en) | 1997-04-16 | 2000-02-15 | Cima Labs Inc. | Rapidly dissolving robust dosage form |
US5976577A (en) | 1997-07-11 | 1999-11-02 | Rp Scherer Corporation | Process for preparing fast dispersing solid oral dosage form |
DE59706616D1 (de) | 1997-10-27 | 2002-04-18 | Gergely Gerhard | Brausezubereitung mit Pflanzenextrakt |
UA68372C2 (en) | 1998-01-22 | 2004-08-16 | Solid pharmaceutical composition containing hexadecylphosphocholine (miltefosine) for oral administration in treatment of leishmaniasis | |
AU2640599A (en) | 1998-02-26 | 1999-09-15 | Banyu Pharmaceutical Co., Ltd. | An orally disintegrating composition and its manufacturing method |
JP3228335B2 (ja) * | 1998-02-26 | 2001-11-12 | 萬有製薬株式会社 | 口腔内崩壊型組成物及びその製造方法 |
ES2293145T3 (es) | 1998-03-09 | 2008-03-16 | Cima Labs Inc. | Dispositivo de manipulacion y envasado de comprimidos blandos. |
DE19822036A1 (de) | 1998-05-15 | 1999-11-18 | Bayer Ag | Brausezubereitungen |
GB2344597A (en) | 1998-12-08 | 2000-06-14 | Procter & Gamble | Effervescence components |
US6683043B1 (en) * | 1998-12-08 | 2004-01-27 | The Procter & Gamble Company | Process for manufacturing effervescence components |
DE19931708A1 (de) | 1999-07-08 | 2001-01-18 | Bayer Ag | Verfahren zur Herstellung schnell zerfallender, fester pharmazeutischer Zubereitungen |
US6426111B1 (en) * | 2000-06-02 | 2002-07-30 | Gerald Phillip Hirsch | Effervescent mixtures and methods of making |
CA2417736A1 (en) | 2000-07-19 | 2002-01-24 | Lavipharm Laboratories, Inc. | Sildenafil citrate solid dispersions having high water solubility |
JP4165224B2 (ja) * | 2001-03-05 | 2008-10-15 | 日本新薬株式会社 | 発泡性組成物 |
US6764601B1 (en) * | 2001-04-16 | 2004-07-20 | Selecto Scientific, Inc. | Method for granulating powders |
FR2823668B1 (fr) * | 2001-04-20 | 2004-02-27 | Ethypharm Lab Prod Ethiques | Comprimes effervescents orodispersibles |
GB0113842D0 (en) | 2001-06-07 | 2001-08-01 | Boots Co Plc | Therapeutic agents |
KR100425755B1 (ko) | 2001-08-27 | 2004-04-03 | 주식회사 원진신약 | 이트라코나졸을 함유하는 조성물 및 그 제조방법 |
US7488496B2 (en) | 2002-03-06 | 2009-02-10 | Christer Rosen | Effervescent compositions comprising bisphosphonates and methods related thereto |
CA2495886C (en) | 2002-03-06 | 2011-05-03 | Lifizz, Inc. | Effervescent compositions comprising bisphosphonates and methods related thereto |
US6811793B2 (en) | 2002-03-11 | 2004-11-02 | Amerilab Technologies, Inc. | Effervescent composition including stevia |
JP4014455B2 (ja) | 2002-06-18 | 2007-11-28 | 江崎グリコ株式会社 | 発泡性粉末飲料 |
US20040137058A1 (en) | 2002-07-09 | 2004-07-15 | Katdare Ashok V. | Effervescent bisphosphonate formulation |
AU2003298776A1 (en) | 2002-11-25 | 2004-06-18 | Purdue Research Foundation | Mannose-based fast dissolving tablets |
AU2003280324A1 (en) | 2002-11-26 | 2004-06-18 | Alk-Abello A/S | Pharmaceutical allergen product |
EP1565258B1 (en) | 2002-11-26 | 2011-12-14 | Universiteit Gent | Process and apparatus for continuous wet granulation of powder material |
US20040265375A1 (en) | 2003-04-16 | 2004-12-30 | Platteeuw Johannes J. | Orally disintegrating tablets |
AT412607B (de) | 2003-08-20 | 2005-05-25 | Gergely Dr & Co | Verfahren zur herstellung von brausegranulaten im vakuum |
US7507396B2 (en) | 2003-10-17 | 2009-03-24 | Amerilab Technologies, Inc. | Effervescent composition and method of making an effervescent composition including a viscous component |
US20060034921A1 (en) | 2004-01-05 | 2006-02-16 | Katdare Ashok V | Effervescent bisphosphonate formulation |
US8545881B2 (en) | 2004-04-19 | 2013-10-01 | Eurand Pharmaceuticals, Ltd. | Orally disintegrating tablets and methods of manufacture |
US8871270B2 (en) | 2004-07-09 | 2014-10-28 | Corn Products Development, Inc | Tablet excipient |
US20080031825A1 (en) | 2004-08-20 | 2008-02-07 | Yisheng Chen | Pharmaceutical Compositions Comprising Effervescent Agents And Fenofibrate |
WO2006092711A2 (en) | 2005-03-02 | 2006-09-08 | Ranbaxy Laboratories Limited | Extended release tablets of metformin and glipizide |
EP2559430B1 (en) | 2005-03-22 | 2015-06-24 | Losan Pharma GmbH | Solubilized Ibuprofen |
WO2007038979A1 (en) | 2005-09-22 | 2007-04-12 | Swissco Development Ag | Effervescent metformin composition and tablets and granules made therefrom |
UA95093C2 (uk) * | 2005-12-07 | 2011-07-11 | Нікомед Фарма Ас | Спосіб одержання кальцієвмісної сполуки |
DE102006054260A1 (de) | 2006-02-28 | 2007-09-27 | Lohmann Animal Health Gmbh & Co. Kg | Wasser stabilisierende Zusammensetzung, Verfahren zu deren Herstellung und deren Verwendung |
US8637076B2 (en) | 2006-06-01 | 2014-01-28 | Cima Labs Inc. | Prednisolone salt formulations |
EP1905428A1 (de) | 2006-09-26 | 2008-04-02 | Losan Pharma GmbH | Ibuprofen-Brausezubereitung mit hoher Lösungsgeschwindigkeit und Verfahren zu deren Herstellung |
CO6070080A1 (es) | 2007-05-15 | 2009-08-31 | Diagnofast Ltda | Composicion farmaceutica solida efervescente que contiene dextrosa y procedimiento para su preparacion |
GR1006148B (el) | 2007-12-07 | 2008-11-10 | Uni-Pharma Κλεων Τσετης, Φαρμακευτικα Εργαστηρια Αβεε | Αναβραζοντα δισκια και αναβραζοντα κοκκια που περιεχουν τρυγικη καρνιτινη |
EP2309998A1 (en) | 2008-08-07 | 2011-04-20 | Phyzz, Inc. | Effervescent tablets/granules |
WO2010117346A2 (en) | 2009-04-10 | 2010-10-14 | Mahmut Bilgic | Stable pharmaceutical compositions with high bioavailibility |
WO2011026080A1 (en) | 2009-08-31 | 2011-03-03 | Wilmington Pharmaceuticals, Llc | Fast disintegrating compositions of meloxicam, processes for preparation, and use to treat arthritis and/or pain |
WO2011079074A1 (en) | 2009-12-24 | 2011-06-30 | Acura Phamaceuticals, Inc. | Pharmaceutical compositions for deterring misuse, abuse, and diversion |
TR201000688A2 (tr) | 2010-01-29 | 2011-08-22 | B�Lg�� Mahmut | Aktif madde olarak sefaklor ve klavulanik asit içeren efervesan formülasyonlar. |
US20110281008A1 (en) | 2010-04-13 | 2011-11-17 | Amerilab Technologies, Inc. | Effervescent tablet with improved dissolution time and method of using the same |
WO2011139251A1 (en) | 2010-05-04 | 2011-11-10 | Mahmut Bilgic | Pharmaceutical compositions comprising cefditoren pivoxil |
WO2011149814A2 (en) | 2010-05-24 | 2011-12-01 | Amerilab Technologies, Inc. | Effervescent composition for forming a gelled composition, tablet for forming a gelled composition, and method of making a gelled composition |
EP2444064A1 (en) | 2010-10-22 | 2012-04-25 | Meliatys | Process for making multiparticulate gastroretentive dosage forms |
TR201009399A2 (tr) | 2010-11-11 | 2012-05-21 | Bi̇lgi̇ç Mahmut | Hızlı çözünen efervesan rosuvastatin formülasyonları. |
AU2011338674B2 (en) | 2010-12-06 | 2017-03-30 | Effrx Pharmaceuticals Sa | Stable effervescent bisphosphonate formulations with rapid solubilization characteristics |
US8580853B2 (en) | 2011-06-13 | 2013-11-12 | Howard PHYKITT | Analgesic composition and method of making the same |
WO2013077822A1 (en) | 2011-11-23 | 2013-05-30 | Mahmut Bilgic | New formulations for treatment of diabetes |
DE102012102414A1 (de) | 2012-03-21 | 2013-10-10 | Michael Dittgen | Pharmazeutische Zusammensetzung für die einmal tägliche Anwendung antidiabetischer Arzneimittel wie Metformin mit Zwei-Puls-Freisetzung |
EP2649989B1 (en) * | 2012-04-13 | 2017-10-18 | King Saud University | Method for preparing a solid dispersion, solid dispersion obtained thereby and use thereof |
CN102860302A (zh) | 2012-09-24 | 2013-01-09 | 发事达(南通)化工有限公司 | 一种芸苔素内酯水分散泡腾片剂及其制备方法 |
CN102823622B (zh) | 2012-09-24 | 2013-12-11 | 发事达(南通)化工有限公司 | 一种草甘膦可溶性泡腾片剂及其制备方法 |
CN102823589B (zh) | 2012-09-24 | 2014-06-04 | 发事达(南通)化工有限公司 | 一种农药水分散泡腾片剂及其制备方法 |
KR20140131205A (ko) | 2013-05-03 | 2014-11-12 | 주식회사 한독 | 수용성 활성성분을 함유하는 서방형 약제학적 조성물 |
WO2017098481A1 (en) | 2015-12-12 | 2017-06-15 | Steerlife India Private Limited | Effervescent compositions of metformin and processes for preparation thereof |
-
2015
- 2015-03-26 RU RU2017110025A patent/RU2706727C2/ru active
- 2015-03-26 AU AU2015316552A patent/AU2015316552C1/en active Active
- 2015-03-26 CA CA3018828A patent/CA3018828C/en active Active
- 2015-03-26 JP JP2017535153A patent/JP6566450B2/ja active Active
- 2015-03-26 CA CA2961445A patent/CA2961445C/en active Active
- 2015-03-26 WO PCT/IB2015/000400 patent/WO2016042372A1/en active Application Filing
- 2015-03-26 KR KR1020177010435A patent/KR102193599B1/ko active IP Right Grant
- 2015-03-26 CN CN201580050053.7A patent/CN106714783A/zh active Pending
- 2015-03-26 US US15/512,515 patent/US20170252295A1/en not_active Abandoned
- 2015-03-26 BR BR112017005362A patent/BR112017005362A2/pt not_active Application Discontinuation
- 2015-03-26 EP EP15720404.1A patent/EP3193843A1/en active Pending
-
2018
- 2018-03-28 JP JP2018061956A patent/JP6748138B2/ja active Active
- 2018-05-03 AU AU2018203085A patent/AU2018203085B2/en active Active
-
2019
- 2019-07-03 JP JP2019124482A patent/JP7010890B2/ja active Active
-
2021
- 2021-08-25 US US17/445,918 patent/US11576855B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CA3018828A1 (en) | 2016-03-24 |
KR20170071500A (ko) | 2017-06-23 |
JP7010890B2 (ja) | 2022-01-26 |
US11576855B2 (en) | 2023-02-14 |
CA3018828C (en) | 2021-05-11 |
KR102193599B1 (ko) | 2020-12-21 |
JP2018138553A (ja) | 2018-09-06 |
US20170252295A1 (en) | 2017-09-07 |
AU2015316552A1 (en) | 2017-05-04 |
JP2017529399A (ja) | 2017-10-05 |
US20220192973A1 (en) | 2022-06-23 |
RU2017110025A3 (ja) | 2018-10-17 |
AU2015316552C1 (en) | 2018-08-23 |
EP3193843A1 (en) | 2017-07-26 |
CA2961445C (en) | 2019-03-26 |
BR112017005362A2 (pt) | 2018-01-23 |
AU2015316552B2 (en) | 2018-05-24 |
WO2016042372A1 (en) | 2016-03-24 |
CN106714783A (zh) | 2017-05-24 |
CA2961445A1 (en) | 2016-03-24 |
RU2017110025A (ru) | 2018-10-17 |
AU2018203085A1 (en) | 2018-05-24 |
AU2018203085B2 (en) | 2019-12-19 |
JP6748138B2 (ja) | 2020-08-26 |
RU2706727C2 (ru) | 2019-11-20 |
JP2019163335A (ja) | 2019-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2019163335A (ja) | 発泡組成物及びそれを製造する方法 | |
CN1183903C (zh) | 低易碎性的口服溶散片及其生产方法 | |
JP4739340B2 (ja) | 口腔内速崩壊性錠 | |
TW200529803A (en) | Extrusion process for forming chemically stable drug multiparticulates | |
JP2013544849A (ja) | 迅速分散顆粒、口腔内崩壊錠、および方法 | |
KR101232114B1 (ko) | 용융 압출에 의해 제조된, 파라세타몰, nsaid 및 당알콜 함유 과립 | |
JP5870690B2 (ja) | 口腔内崩壊錠及びその製造方法 | |
JPH093071A (ja) | S(+)−エトドラクの経口製剤 | |
JP2008007420A (ja) | 造粒物 | |
JP5054940B2 (ja) | 錠剤組成物 | |
EP1404296B1 (en) | Effervescent formulations of non-steroidal anti-inflammatory drugs | |
JPWO2018124062A1 (ja) | 含量均一性を改善した製剤の製造方法 | |
JP2002515422A (ja) | 発泡性製剤 | |
CN112770779B (zh) | 纤维素组合物、片剂及口腔崩解片 | |
JP3341769B1 (ja) | 分岐鎖アミノ酸含有チュアブル剤 | |
RU2764032C1 (ru) | Быстрорастворимая лекарственная форма индометацина и способ ее получения (варианты) | |
EP2939661B1 (en) | Novel microgranular formulation | |
CN115212173A (zh) | 一种盐酸氨溴索球形缓释微粒、制备方法及用途 | |
Venkataramudu et al. | SOLUBILITY ENHANCEMENT OF AMISULPRIDE BY COMPLEXATION TECHNIQUE AND PREPARATION OF FAST DISSOLVING TABLET (FDT) | |
Eemana | Formulation and Evaluation of Deferasirox Dispersible Tablets | |
JP2013087056A (ja) | 光沢コーティング錠の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170418 Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170508 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170418 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180105 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180328 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20180723 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181126 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20181127 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20190122 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190319 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190612 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190702 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190724 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6566450 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |